Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicentre, Open-Label Study of Modi-1 Moditope in Patients With Breast, Head and Neck, Ovarian, or Renal Cancer

NCT05329532 is registered in ClinicalTrials.gov with Scancell Ltd as lead sponsor.

NCT NCT05329532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05329532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicentre, Open-Label Study of Modi-1 Moditope in Patients With Breast, Head and Neck, Ovarian, or Renal Cancer
Lead sponsor
Scancell Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 7, 2022
Completion date
July 1, 2027
Enrollment
168 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

high grade ovarian serous adenocarcinoma, renal cell cancer, squamous cell carcinoma of the head and neck, triple negative breast cancer